ArticleFrontiers in oncology2022

POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma.

Sheela Rao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.